AC Immune SA (ACIU)

2,4400 -0,0600 (-2,40%) Al cierre: 04:00PM EDT

AC Immune SA

Building B
EPFL Innovation Park
Lausanne 1015
Switzerland
41 21 345 91 21
https://www.acimmune.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 133

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Andrea Pfeifer Ph.D.	Co-Founder, CEO & Director	1,08M	N/A	1957
Mr. Christopher Roberts	CFO & VP of Finance	N/A	N/A	1990
Mr. Piergiorgio Donati	Chief Technical Operations Officer	N/A	N/A	1971
Mr. Jean-Fabien Monin	Chief Administrative Officer	N/A	N/A	1971
Mr. Howard Donovan	Chief HR Officer	N/A	N/A	1976
Ms. Madiha Derouazi	Chief Scientific Officer	N/A	N/A	1973
Dr. Gary Anthony Waanders Ph.D.	Senior VP of Investor Relations & Corporate Communications	N/A	N/A	1964
Mr. Alexandre Caratsch	General Counsel	N/A	N/A	1966
Mr. Julian Snow	VP of U.S. Finance & Corporate Development	N/A	N/A	N/A
Dr. David T. Hickman	Head of AD - SME	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies. Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Gobierno corporativo

El ISS Governance QualityScore de AC Immune SA, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.